AR098846A1 - Inhibidores del transporte de glucosa - Google Patents
Inhibidores del transporte de glucosaInfo
- Publication number
- AR098846A1 AR098846A1 ARP140104777A ARP140104777A AR098846A1 AR 098846 A1 AR098846 A1 AR 098846A1 AR P140104777 A ARP140104777 A AR P140104777A AR P140104777 A ARP140104777 A AR P140104777A AR 098846 A1 AR098846 A1 AR 098846A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- heteroaryl
- halo
- phenyl
- Prior art date
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract 2
- 239000008103 glucose Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 26
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 12
- 125000001072 heteroaryl group Chemical group 0.000 abstract 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 9
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 8
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 6
- -1 cyano, hydroxy Chemical group 0.000 abstract 4
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 1
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 102000058063 Glucose Transporter Type 1 Human genes 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 108091006296 SLC2A1 Proteins 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos químicos que inhiben al transportador de glucosa 1 (GLUT1); métodos para preparar dichos compuestos; composiciones farmacéuticas y combinaciones que comprenden dichos compuestos; uso de dichos compuestos para fabricar una composición farmacéutica para el tratamiento o profilaxis de una enfermedad; y compuestos intermediarios que son útiles en la preparación de dichos compuestos. Reivindicación 1: Un compuesto de fórmula general (1), donde: R¹ representa un grupo C₁₋₃-alquilo, halo-C₁₋₃-alquilo, ciano, -C(=O)O-R¹⁰ o -C(=O)N(R¹⁰ᵃ)R¹⁰ᵇ; R² representa un grupo C₁₋₃-alquilo, halo-C₁₋₃-alquilo, ciano, -C(=O)O-R¹⁰ o -C(=O)N(R¹⁰ᵃ)R¹⁰ᵇ; R³ representa un grupo seleccionado entre: arilo, heteroarilo, C₅₋₆-cicloalquilo, y heterocicloalquilo de 5 ó 6 miembros; donde dicho grupo heterocicloalquilo de 5 ó 6 miembros está opcionalmente benzocondensado; donde dicho grupo arilo, heteroarilo, C₅₋₆-cicloalquilo, y heterocicloalquilo de 5 ó 6 miembros está opcionalmente sustituido, una o más veces, en forma idéntica o diferente, con -(L²)ₚ-R⁷; y donde dos grupos -(L²)ₚ-R⁷, en el caso de estar presentes en posición orto entre si en un grupo arilo o heteroarilo opcionalmente forman un puente seleccionado entre: *-C₃₋₈-alquilen-*, *-O(CH₂)₂O-*, *-O(CH₂)O-*, *-O(CF₂)O-*, *-CH₂C(R¹⁰ᵃ)(R¹⁰ᵇ)O-*, *-C(=O)N(R¹⁰ᵃ)CH₂-*, *-N(R¹⁰ᵃ)C(=O)CH₂O-*, *-NHC(=O)NH-*; donde cada * representa el punto de unión a dicho grupo arilo o heteroarilo; R⁴ᵃ representa un átomo de hidrógeno o un átomo de halógeno o un grupo seleccionado entre: ciano, hidroxi, C₁₋₃-alquilo, halo-C₁₋₃-alquilo, C₁₋₃-alcoxi, halo-C₁₋₃-alcoxi, C₃₋₇-cicloalquilo, heterocicloalquilo de entre 4 y 7 miembros, -C(=O)-OR¹⁰, -C(=O)N(R¹⁰ᵃ)R¹⁰ᵇ, -C(=O)-N(R¹⁰ᵃ)-S(=O)₂-R¹⁰, -SR¹⁰, -S(=O)-R¹⁰, -S(=NR¹¹)-R¹⁰, -S(=O)₂-R¹⁰, -S(=O)₂-N(R¹⁰ᵃ)R¹⁰ᵇ, -S(=O)(=NR¹¹)-R¹⁰, -N(R¹⁰ᵃ)R¹⁰ᵇ; R⁴ᵇ representa un átomo de hidrógeno o un grupo seleccionado entre: C₁₋₃-alcoxi, C₁₋₃-alquilo, ciano; o R⁴ᵃ y R⁴ᵇ forman juntos un grupo -C₃₋₅-alquileno; R⁵ᵃ, R⁵ᵇ, R⁵ᶜ, R⁵ᵈ en forma independiente entre sí representan un átomo de hidrógeno, un átomo de halógeno o un grupo seleccionado entre: ciano, -NO₂, C₁₋₃-alquilo, halo-C₁₋₃-alquilo, C₁₋₃-alcoxi, halo-C₁₋₃-alcoxi, fenilo, heteroarilo, -C(=O)R¹⁰, -C(=O)N(H)R¹⁰, -C(=O)N(R¹⁰ᵃ)R¹⁰ᵇ, -C(=O)O-R¹⁰, -N(R¹⁰ᵃ)R¹⁰ᵇ, -N(H)C(=O)R¹⁰, -N(R¹⁰ᵃ)C(=O)R¹⁰ᵇ, -N(H)C(=O)N(R¹⁰ᵃ)R¹⁰ᵇ, -N(R¹⁰ᵃ)C(=O)N(R¹⁰ᵇ)R¹⁰ᶜ, -N(R¹⁰ᵃ)C(=O)C(=O)N(R¹⁰ᵇ)R¹⁰ᶜ, -N(H)C(=O)OR¹⁰, -N(R¹⁰ᵃ)C(=O)OR¹⁰ᵇ, -N(H)S(=O)₂R¹⁰, -N(R¹⁰ᵃ)S(=O)₂R¹⁰ᵇ, -OR¹⁰, -O(C=O)R¹⁰, -O(C=O)N(R¹⁰ᵃ)R¹⁰ᵇ, -O(C=O)OR¹⁰, -SR¹⁰, -S(=O)R¹⁰, -S(=O)₂R¹⁰, -S(=O)₂N(H)R¹⁰, -S(=O)₂N(R¹⁰ᵃ)R¹⁰ᵇ o -S(=O)(=NR¹⁰ᵃ)R¹⁰ᵇ, donde dicho grupo fenilo o heteroarilo está opcionalmente sustituido una o más veces, en forma idéntica o diferente, con un grupo seleccionado entre: halo, ciano, C₁₋₃-alquilo, halo-C₁₋₃-alquilo, C₁₋₃-alcoxi; R⁶ representa un átomo de hidrógeno o un grupo seleccionado entre: C₁₋₃-alquilo, C₁₋₃-alcoxi-(L²)-, hidroxi-C₁₋₃-alquilo, aril-(L²)-, heteroaril-(L²)-; R⁷ representa un grupo seleccionado entre: oxo, C₁₋₆-alquilo, C₃₋₇-cicloalquilo, heterocicloalquilo de entre 4 y 7 miembros, halo-C₁₋₄-alquilo, hidroxi-C₁₋₄-alquilo, ciano-C₁₋₄-alquilo, C₂₋₄-alquenilo, C₂₋₄-alquinilo, C₁₋₄-alcoxi, halo-C₁₋₄-alcoxi, -OH, -CN, halo, -C(=O)R⁸, -C(=O)-O-R⁸, -C(=O)N(R⁸ᵃ)R⁸ᵇ, -N(R¹⁰ᵃ)R¹⁰ᵇ, -S(=O)₂R⁸, -S(=O)(=NR¹¹)-R¹⁰, fenilo, heteroarilo de 5 ó 6 miembros; R⁸ representa un átomo de hidrógeno o un grupo C₁₋₆-alquilo, halo-C₁₋₃-alquilo, ciano-C₁₋₄-alquilo, C₁₋₃-alcoxi-C₁₋₃-alquilo, C₃₋₇-cicloalquilo, fenilo, heteroarilo de 5 ó 6 miembros o bencilo; R⁸ᵃ, R⁸ᵇ representan, en forma independiente entre sí, un átomo de hidrógeno, o un grupo C₁₋₁₀-alquilo, C₃₋₇-cicloalquilo, (C₃₋₇-cicloalquil)-(L³)-, C₃₋₆-alquenilo, C₃₋₆-alquinilo, heterocicloalquilo de entre 4 y 10 miembros, (heterocicloalquilo de entre 4 y 10 miembros)-(L³)-, fenilo, heteroarilo, fenil-(L³)-, (fenil)-O-(L³)-, heteroaril-(L³)-, o (aril)-(heterocicloalquilo de entre 4 y 10 miembros)-; donde dicho grupo C₁₋₁₀-alquilo, C₃₋₇-cicloalquilo, (C₃₋₇-cicloalquil)-(L³)-, C₃₋₆-alquenilo, C₃₋₆-alquinilo, heterocicloalquilo de entre 4 y 10 miembros, (heterocicloalquilo de entre 14 y 10 miembros)-(L³)-, fenilo, heteroarilo, fenil-(L³)-, (fenil)-O-(L³)-, heteroaril-(L³)-, y (aril)-(heterocicloalquilo de entre 4 y 10 miembros)- está opcionalmente sustituido una o más veces, en forma idéntica o diferente, con R⁹; o R⁸ᵃ y R⁸ᵇ, junto con el átomo de nitrógeno al cual se unen, representan un grupo heterocicloalquilo de entre 4 y 10 miembros, donde dicho grupo heterocicloalquilo de entre 4 y 10 miembros está opcionalmente sustituido una o más veces, en forma idéntica o diferente, con R⁹; R⁹ representa un átomo de halógeno, o un grupo oxo, C₁₋₃-alquilo, halo-C₁₋₃-alquilo, hidroxi-C₁₋₃-alquilo, -CN, -C(=O)R¹⁰, -C(=O)N(H)R¹⁰, -C(=O)N(R¹⁰ᵃ)R¹⁰ᵇ, -C(=O)O-R¹⁰, -N(R¹⁰ᵃ)R¹⁰ᵇ, -NO₂, -N(H)C(=O)R¹⁰, -N(R¹⁰ᵃ)C(=O)R¹⁰ᵇ, -N(H)C(=O)N(R¹⁰ᵃ)R¹⁰ᵇ, -N(R¹⁰ᵃ)C(=O)N(R¹⁰ᵇ)R¹⁰ᶜ, -N(H)C(=O)OR¹⁰, -N(R¹⁰ᵃ)C(=O)OR¹⁰ᵇ, -N(H)S(=O)₂R¹⁰, -N(R¹⁰ᵃ)S(=O)₂R¹⁰ᵇ, -OR¹⁰, -O(C=O)R¹⁰, -O(C=O)N(R¹⁰ᵃ)R¹⁰ᵇ, -O(C=O)OR¹⁰, -SR¹⁰, -S(=O)R¹⁰, -S(=O)₂R¹⁰, -S(=O)₂N(H)R¹⁰, -S(=O)₂N(R¹⁰ᵃ)R¹⁰ᵇ, -S(=O)(=NR¹⁰ᵃ)R¹⁰ᵇ o tetrazolilo; o dos grupos R⁹ presentes en posición orto entre sí en un anillo fenilo o heteroarilo forman un puente seleccionado entre: *-C₃₋₅-alquilen-*, *-O(CH₂)₂O-*, *-O(CH₂)O-*, *-O(CF₂)O-*, *-CH₂C(R¹⁰ᵃ)(R¹⁰ᵇ)O-*, *-C(=O)N(R¹⁰ᵃ)CH₂-*, *-N(R¹⁰ᵃ)C(=O)CH₂O-*, *-NHC(=O)NH-*; donde cada * representa el punto de unión a dicho anillo fenilo o heteroarilo; R¹⁰, R¹⁰ᵃ, R¹⁰ᵇ, R¹⁰ᶜ representan, en forma independiente entre si, un átomo de hidrógeno o un grupo seleccionado entre: C₁₋₃-alquilo, halo-C₁₋₃-alquilo, hidroxi-C₁₋₃-alquilo, C₁₋₃-alcoxi-C₁₋₃-alquilo, C₃₋₇-cicloalquilo, donde dicho grupo C₁₋₃-alquilo está opcionalmente sustituido una vez con -N(R¹²)R¹²ᵃ; o R¹⁰ᵃ y R¹⁰ᵇ, junto con el átomo de nitrógeno al cual se unen, representan un grupo heterocicloalquilo de entre 4 y 7 miembros, donde dicho grupo heterocicloalquilo de entre 4 y 7 miembros está opcionalmente sustituido una o más veces, en forma idéntica o diferente, con R¹³; R¹¹ representa un átomo de hidrógeno o un grupo ciano, C₁₋₃-alquilo, -C(=O)R¹⁰, -C(=O)N(H)R¹⁰, -C(=O)N(R¹⁰ᵃ)R¹⁰ᵇ o -C(=O)O-R¹⁰; R¹², R¹²ᵃ representan, en forma independiente entre sí, un átomo de hidrógeno o un grupo C₁₋₃-alquilo, o, R¹², R¹²ᵃ junto con el átomo de nitrógeno al cual se unen, representan un grupo heterocicloalquilo de entre 4 y 7 miembros; R¹³ representa un átomo de halógeno o un grupo ciano, hidroxi, oxo, C₁₋₃-alquilo, trifluorometilo, -C(=O)R¹⁰ o -C(=O)O-R¹⁰; L¹ representa un grupo seleccionado entre: -C₁₋₄-alquileno, -CH₂-CH=CH-, -C(fenil)(H)-, -CH₂-CH₂-O-, -CH₂-C(=O)-N(H)-, -CH₂-C(=O)-N(R¹⁰ᵃ)-; L² representa un grupo seleccionado entre: -CH₂-, -CH₂-CH₂-, -CH₂-CH₂-CH₂-; L³ representa un grupo -C₁₋₆-alquileno; p es el número entero 0 ó 1; o un tautómero, un estereoisómero, un N-óxido, un hidrato, un solvato, o una sal del mismo, o una mezcla de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13198787 | 2013-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR098846A1 true AR098846A1 (es) | 2016-06-15 |
Family
ID=49880508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140104777A AR098846A1 (es) | 2013-12-20 | 2014-12-19 | Inhibidores del transporte de glucosa |
Country Status (8)
Country | Link |
---|---|
US (1) | US20170037028A1 (es) |
EP (1) | EP3083598A1 (es) |
JP (1) | JP2017500333A (es) |
CN (1) | CN106029647A (es) |
AR (1) | AR098846A1 (es) |
CA (1) | CA2934391A1 (es) |
UY (1) | UY35905A (es) |
WO (1) | WO2015091428A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170226081A1 (en) * | 2014-07-24 | 2017-08-10 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
US20170210738A1 (en) * | 2014-07-24 | 2017-07-27 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
WO2016202935A1 (en) * | 2015-06-19 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
WO2016202898A1 (en) * | 2015-06-19 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
CN112294815B (zh) * | 2020-09-22 | 2021-08-31 | 厦门市中医院 | 化合物bay-876在制备治疗和/或预防肝损伤药物中的用途 |
EP4333822A1 (en) | 2021-05-03 | 2024-03-13 | Lead Discovery Center GmbH | Composition comprising an inhibitor of mitochondrial transcription |
EP4347568A1 (en) * | 2021-05-27 | 2024-04-10 | Protego Biopharma, Inc. | Heteroaryl diamide ire1/xbp1s activators |
CN115894447A (zh) * | 2021-09-22 | 2023-04-04 | 成都先导药物开发股份有限公司 | Mettl3抑制剂及其用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE503170A (es) * | 1975-09-02 | |||
CA1156850A (en) * | 1980-12-23 | 1983-11-15 | Anson R. Cooke | Male gametocide method of small grain plant |
JP2002528456A (ja) * | 1998-10-23 | 2002-09-03 | ファイザー・インク | 性的機能障害の処置のためのピラゾロピリミジノン系cGMP阻害薬 |
US6699879B1 (en) * | 1999-02-12 | 2004-03-02 | Smithkline Beecham P.L.C. | Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists |
WO2002023986A1 (fr) * | 2000-08-25 | 2002-03-28 | Sankyo Company, Limited | Derives de 4-acylaminopyrazole |
GB0106661D0 (en) * | 2001-03-16 | 2001-05-09 | Pfizer Ltd | Pharmaceutically active compounds |
GB0124939D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0327319D0 (en) * | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
JP2010527344A (ja) * | 2007-05-18 | 2010-08-12 | インヒブオーエックス リミテッド | ビシクロスルホニル酸(bcsa)化合物及び治療薬としてのその使用 |
US20120116027A1 (en) * | 2008-11-13 | 2012-05-10 | Jakob Ewald Rasmussen | Process for the purification of human growth hormone polypeptides using affinity resins comprising specific ligands |
EP2408766A1 (en) * | 2009-03-18 | 2012-01-25 | Schering Corporation | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase |
CN103037690B (zh) * | 2010-03-24 | 2016-04-27 | 俄亥俄州立大学 | 用于葡萄糖转运抑制的组合物和方法 |
CN102924374B (zh) * | 2012-02-15 | 2014-04-16 | 湖北欣瑞康医药科技有限公司 | 喹啉-4-羧酸衍生物的制备方法 |
-
2014
- 2014-12-16 CN CN201480075941.XA patent/CN106029647A/zh active Pending
- 2014-12-16 WO PCT/EP2014/077879 patent/WO2015091428A1/en active Application Filing
- 2014-12-16 US US15/106,814 patent/US20170037028A1/en not_active Abandoned
- 2014-12-16 JP JP2016541272A patent/JP2017500333A/ja active Pending
- 2014-12-16 CA CA2934391A patent/CA2934391A1/en not_active Abandoned
- 2014-12-16 EP EP14821117.0A patent/EP3083598A1/en not_active Withdrawn
- 2014-12-19 UY UY0001035905A patent/UY35905A/es not_active Application Discontinuation
- 2014-12-19 AR ARP140104777A patent/AR098846A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN106029647A (zh) | 2016-10-12 |
JP2017500333A (ja) | 2017-01-05 |
EP3083598A1 (en) | 2016-10-26 |
US20170037028A1 (en) | 2017-02-09 |
WO2015091428A1 (en) | 2015-06-25 |
CA2934391A1 (en) | 2015-06-25 |
UY35905A (es) | 2015-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR098846A1 (es) | Inhibidores del transporte de glucosa | |
AR116993A2 (es) | Compuestos heterociclos bicíclicos y sus usos en terapia | |
AR105122A1 (es) | INHIBIDORES DE METALO-b-LACTAMASA | |
AR103574A1 (es) | Compuestos tricíclicos y usos de lo mismos en medicina | |
AR108356A1 (es) | Derivados aromáticos de sulfonamida | |
AR103252A1 (es) | Compuestos de quinazolina | |
AR102948A1 (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo como inhibidores del receptor p2x3 | |
AR107488A1 (es) | Compuestos de benzopirazol y análogos de éstos | |
AR103064A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR093339A1 (es) | Analogos de spliceostatina y metodos para su preparacion | |
AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
AR107798A1 (es) | Compuestos derivados de piridazin y sus composiciones farmacéuticas para el tratamiento de la fibrosis | |
AR106865A1 (es) | Piridinas sustituidas y métodos de uso | |
AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR093036A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
AR092288A1 (es) | Ligandos del receptor ep1 | |
AR097756A1 (es) | Derivados de fenilalanina sustituidos | |
AR112086A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
AR120246A1 (es) | Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1 | |
AR109950A1 (es) | INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA | |
AR109651A1 (es) | Compuestos de piridina y pirazina como inhibidores de ripk2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |